Clinical Trials & Pipeline
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to demonstrate clinical proof of concept for microRNA replacement therapy.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
November 23, 2015
Mirna Announces the Publication of New Data Supporting Potential Immune-Related Mechanism for Anti-Cancer Activity of MRX34
November 13, 2015
Mirna Reports Third Quarter Financial Results and Recent Highlights
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.